Tesamorelin vs HGH: Which Actually Raises IGF-1 More?

Watch the full video on Rumble: https://rumble.com/v7hrut6-tesamorelin-vs-hgh-which-actually-raises-igf-1-more.html

Tesamorelin vs HGH: Which One Actually Raises IGF-1 More?

HGH raises IGF-1 higher and faster than tesamorelin does, and the reason has nothing to do with one being stronger than the other. They are both pulling on the same chain. One of them just starts further down it.

HGH and tesamorelin are acting on the same pathway of growth hormone IGF-1 production in your body.

That pathway runs in a line. Your hypothalamus releases a signal called GHRH, which is growth hormone releasing hormone, and that signal travels a short distance to your pituitary gland, and your pituitary responds by releasing growth hormone in a pulse. That growth hormone reaches your liver, and your liver produces IGF-1, which is the hormone doing most of the work people are actually chasing.

So there are two places you can intervene. Push on the signal at the top, or add the finished product at the bottom.

Tesamorelin is just copying the GHRH signal that tells your pituitary gland to release growth hormone, right? Adding growth hormone is just skipping the pituitary gland and dropping that finished hormone straight in your blood, okay? Either way, the product is growth hormone and your liver, in turn, turns that into IGF-1.

That difference in entry point is what sets the ceiling.

There's actually a study that said basically in 13 healthy men, two weeks of tesamorelin pushed IGF-1 by up to 181 micrograms per liter, and with HGH, IGF-1 tripled in seven days. Two weeks of signaling the pituitary moved the number meaningfully. One week of direct hormone moved it more, in half the time.

The thing about tesamorelin versus HGH is tesamorelin, it's going to have a cap on the effective dosage, okay? And the reason for that is because your pituitary is only going to respond to so much growth hormone signal.

Think of the pituitary as a tank that fills and empties. GHRH opens the valve. If the tank is low, opening the valve wider does nothing, because there is nothing left to let out. Your body also runs a brake on this system called somatostatin, which is the hormone that shuts growth hormone release off, and the harder you push the signal, the more that brake engages.

Injected growth hormone has no tank and no brake. You are not asking a gland for anything. The dose you inject is the dose you get, which is why the IGF-1 response keeps climbing with dose in a way tesamorelin's does not.

What tesamorelin keeps is the shape of the release. The pituitary fires in pulses, mostly at night, and IGF-1 feeds back on the hypothalamus to quiet things down when levels get high. That loop stays intact, and that is why people on tesamorelin tend to report better sleep and less of the puffiness and joint ache that show up when IGF-1 sits flat and high around the clock.

That is where most of the confusion comes from. Someone starts tesamorelin, feels better within a couple of weeks, and concludes it is working faster. The subjective response arrives early. The number climbs slowly and then stops climbing.

Bottom line here is tesamorelin is not working faster, it just feels better sooner.

So pick based on the target. If you want a specific IGF-1 number in a week, growth hormone gets you there and tesamorelin will likely stall before it does. If you want a moderate lift you can hold for a long time without chasing dose or fighting side effects, tesamorelin's ceiling is the feature, because the thing stopping you from going higher is the same feedback loop keeping you comfortable.

And if you are already on tesamorelin and your IGF-1 has flattened out, raising the dose is usually the wrong move. You have hit the pituitary's response limit, not an underdosing problem, and the extra peptide goes into a brake that is already pressed.

Research: Stanley TL, et al. Effects of tesamorelin on IGF-1 and growth hormone in healthy men.